FDA Puts a Stop to Avandia Side Effects Study

Recent weeks have seen a federal panel of experts debate whether or not Avandia should remain on the market on the heels of all of these reports of Avandia side effects.  While the panel narrowly voted to allow the drug to remain available for the time being, it also reserved the right to review additional findings that were supposed to define whether the benefits of using Avandia outweigh the risks of serious Avandia side effects that include heart attacks and strokes.  An enormous study known as the 'TIDE' study had been commissioned to determine the answer to this question.

However, the FDA has stepped in and halted the process of recruiting subjects for this study.  TIDE was supposed to track as many as 16,000 patients, with some using Avandia, others using Actos, which is a competitor of Avandia and a third group using no medication.  To date, approximately 1,100 subjects have enrolled in the study.  Based on the FDA's position, there will be no additional recruitment for TIDE allowed.

The Risk of Avandia Side Effects Are Too Great

Basically, the FDA put a stop to this study because the risk of developing Avandia side effects was seen as too high and potentially problematic.  People should not partake in a study where there is a chance to suffer a heart attack or a stroke.  Therefore, TIDE has been put on hold and other outlets will be explored to define whether or not Avandia should remain on the market.

Overall, this issue is not completely relevant to those who have already suffered as a result of using Avandia.  If this includes you or someone you love, contact the Avandia side effects lawyers at Phillips & Associates today to schedule a free initial consultation.